# Eli Lilly and Company

Eli Lilly and Company is an Asset Manager based in Indianapolis, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Indianapolis, United States
- **Region:** North America
- **Address:** Indianapolis, IN, United States
- **Founded:** 1876
- **Assets under management:** Undisclosed
- **Website:** lilly.com
- **LinkedIn:** https://www.linkedin.com/company/eli-lilly-china

## Regulatory record

- **Reports private funds:** No

## About

Eli Lilly & Company is a corporate investor based in Indianapolis, US. It manages approximately $75.6 billion in assets across 11 funds, primarily focused on North America.

## Sectors

- Biotech
- Pharmaceuticals
- Healthcare Services
- AI/ML

## Offices

- San Diego
- New York
- Shanghai

## People

- Dave Ricks — Chair and CEO
- Anat Ashkenazi — CFO (until 2024)
- Luca Visinelli — EVP, International
- Dan Skovronsky — EVP, Chief Scientific Officer

## Questions

### Who runs investment decisions at Eli Lilly?

CEO Dave Ricks and Chief Scientific Officer Dan Skovronsky set the R&D investment strategy, with board oversight. CFO Anat Ashkenazi departed in 2024; Lucinda Meyer now serves as interim CFO. Capital allocation decisions for acquisitions and R&D projects go through an internal executive committee.

### How does Eli Lilly source proprietary drug candidates?

Lilly sources primarily through internal discovery labs in Indianapolis, San Diego, and Shanghai. It also licenses early-stage biotech molecules and executes bolt-on acquisitions like MorphiC in 2024. The company does not rely on external VC funds for deal flow.

### Does Eli Lilly participate in fund commitments or only direct investments?

Lilly does not commit capital to external GP funds. All investment is direct into internal R&D programs, licensing deals, and M&A. It does not operate a venture capital arm, though it has made minority investments in companies like Sigilon Therapeutics.

### What investment stages does Eli Lilly typically target?

Lilly invests across the drug development lifecycle: early-stage preclinical discovery through its labs, phase 1-3 clinical trials, and commercial-stage launches. Acquisitions focus on assets in phase 2 or later to de-risk pipeline additions.

### Which sectors does Eli Lilly explicitly avoid?

Lilly does not invest in non-healthcare sectors like real estate, energy, or technology outside of health IT. It also generally avoids generic drugs and animal health after spinning off Elanco in 2018.

### How is Eli Lilly related to the Lilly Endowment?

The Lilly Endowment is a separate charitable trust created by members of the Lilly family. It holds about 12% of Lilly's shares but has no operational control over the company. The endowment's grants do not fund Lilly's R&D; they focus on community, education, and religious causes.

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/eli-lilly-and-company

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology